/
We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care.
The business is unprofitable at the operating level (-188.25% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 15.3%, still solid. Margins contracted 18.8pp, which offsets some of the top-line progress.
Negative free cash flow of -$23M. The business is consuming cash, not generating it. Operating margin contracted 18.8pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$14M
▲ +15.3% YoY
Net Income (TTM)
-$27M
▼ -27.2% YoY
Op. Margin
-200.74%
▼ -18.8pp YoY
ROIC
-149.26%
▲ +1008.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$24M
▼ -13.4% YoY
Op. Cash Flow (TTM)
-$24M
▼ -13.8% YoY
Net Debt
N/A
Cash & Equiv.
N/A
Continue Research